Lengthy post-marketing experience with Sanofi’s rheumatoid arthritis drug Arava (leflunomide) not only guided FDA’s safety evaluation of Aubagio (teriflunomide), it rendered unnecessary a Risk Evaluation and Mitigation Strategy for the new multiple sclerosis treatment.
Teriflunomide is the active and primary metabolite of leflunomide, which has been marketed in the U.S. for more than a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?